ArticleBMC cancer2025
Identification and validation of SUN modification-related anti-PD-1 immunotherapy-resistance signatures to predict prognosis and immune microenvironment status in glioblastoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundUbiquitination, SUMOylation, and neddylation (collectively termed SUN modifications) play crucial roles in cancer pathogenesis and immunotherapy resistance. This study investigated the prognostic significance of these modifications in glioblastoma (GBM).
methodsKey genes associated with SUN modifications and anti-PD-1 resistance were identified using integrated bioinformatic approaches, including differential expression analysis, Weighted Gene Co-expression Network Analysis (WGCNA), and machine learning algorithms. The expression levels of identified genes were subsequently validated in GBM cell lines using RT-qPCR and Western blotting. A prognostic risk model was constructed based on the key genes. Single-cell RNA sequencing (scRNA-seq) and spatial transcriptome analysis were further employed to characterize gene expression patterns.
resultsSix prognostic genes (PLK2, CDC73, PSMC2, SOCS3, ETV4, and LMO7) were identified. CDC73, PSMC2, SOCS3, and ETV4 were upregulated, while PLK2 and LMO7 were downregulated in GBM cells. The six-gene prognostic risk model demonstrated excellent predictive performance, achieving an Area Under the Curve (AUC) exceeding 0.9. The derived risk score exhibited significant correlations with clinical features, immune infiltration levels, and drug sensitivity profiles. Furthermore, scRNA-seq and spatial transcriptome analysis revealed high SOCS3 expression specifically in monocytes and macrophages, suggesting its potential role in mediating the activity of these immune cells to influence tumor progression and drug sensitivity in GBM.
conclusionThis study established a robust six-gene prognostic model related to SUN modifications and anti-PD-1 therapy in GBM. The model demonstrates strong predictive ability and correlates with clinically relevant parameters, highlighting its potential utility for survival prediction and guiding therapeutic management decisions in GBM patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.